Q3 Earnings Estimate for Immunocore Issued By HC Wainwright

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Immunocore to a loss of $0.08 per share from a previous loss estimate of $0.25, while maintaining a “Buy” rating and $100 price target.
• The firm projects Immunocore will become profitable in 2026, forecasting $0.11 in full-year EPS, followed by $1.36 in 2027 and substantial longer-term earnings growth.
• Immunocore’s latest quarterly results missed expectations, with an EPS loss of $0.02 versus a projected loss of $0.01 and revenue of $115.93 million versus estimates of $148.57 million. Analysts overall assign the stock a “Moderate Buy” rating with an average price target of $57.29.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Immunocore in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.08) per share for the quarter, up from their previous estimate of ($0.25). HC Wainwright has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Immunocore's current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for Immunocore's Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.11 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.29 EPS, FY2027 earnings at $1.36 EPS, FY2029 earnings at $7.70 EPS and FY2030 earnings at $10.87 EPS.

Other analysts have also recently issued reports about the stock. Zacks Research raised shares of Immunocore from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immunocore in a research note on Monday, July 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Immunocore in a research report on Friday, July 17th. Mizuho raised their price target on Immunocore from $34.00 to $35.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Finally, Morgan Stanley set a $43.00 price target on Immunocore in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Immunocore currently has an average rating of "Moderate Buy" and an average price target of $57.29.

Immunocore Stock Performance

NASDAQ:IMCR opened at $34.20 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. The firm has a market cap of $1.74 billion, a PE ratio of -92.43 and a beta of 0.74. The firm has a 50 day simple moving average of $32.06 and a 200-day simple moving average of $31.32. Immunocore has a 1-year low of $27.56 and a 1-year high of $40.71.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $115.93 million for the quarter, compared to analyst estimates of $148.57 million. Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%.

Institutional Trading of Immunocore

A number of institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in Immunocore by 45.1% in the first quarter. Royal Bank of Canada now owns 44,011 shares of the company's stock valued at $1,306,000 after purchasing an additional 13,689 shares during the period. Geode Capital Management LLC raised its holdings in shares of Immunocore by 40.1% during the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company's stock valued at $1,632,000 after buying an additional 14,877 shares during the period. Marshall Wace LLP boosted its holdings in Immunocore by 425.8% in the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company's stock worth $4,601,000 after acquiring an additional 118,728 shares during the period. Sei Investments Co. acquired a new stake in Immunocore in the second quarter valued at approximately $983,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Immunocore by 108.0% during the second quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company's stock valued at $4,480,000 after purchasing an additional 74,128 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $0.11 from a prior estimate of ($0.45), a major improvement that implies Immunocore could become profitable sooner than previously expected.
• Positive Sentiment: The firm increased its Q3 2026 and Q4 2026 estimates to losses of ($0.08) and ($0.04), respectively, from prior forecasts of ($0.25) and ($0.20). The narrower projected losses point to improving operating performance.
• Positive Sentiment: Forecasts for 2027 were raised substantially: Q1 EPS increased to $0.18 from $0.07, Q2 to $0.29 from $0.17, and full-year EPS to $1.36 from $0.90.
• Positive Sentiment: Longer-term estimates also moved higher, with FY2028 EPS rising to $4.53, FY2029 to $7.70, and FY2030 to $10.87. These upgrades reinforce the analyst’s expectation for accelerating earnings growth.
• Positive Sentiment: HC Wainwright’s $100 target is well above Immunocore’s recent trading level near $34, potentially attracting investors focused on the company’s long-term commercial and earnings potential.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source